Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells.

Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Abstract Text:

As noted in previous articles in this series, the very heterogeneous MHC class I and II molecules present peptide antigens to T-cells. However, there is another family of less heterogeneous MHC-related molecules. CD1 molecules present lipid antigens, oftentimes to 2 other distinct families of T-cells: gammadelta T-cells (named because they bear a T-cell antigen receptor consisting of a gamma chain and a delta chain rather than the alpha chain/beta chain heterodimer on most T-cells) and iNKT cells (T-cells that bear markers previously defined on natural killer cells). CD1 molecules and the gammadelta T-cells and iNKT cells to which they present antigens have fundamental responsibilities for immune surveillance over intracellular pathogens and serve other roles that place them at the boundary between innate and acquired immunity. The gammadelta T-cell has been implicated in the pathogenesis of many diseases, rheumatologic and otherwise, suggesting that better understanding of these cells, and of CD1 molecules, may help us explain the immunopathogenesis of some inflammatory diseases and how to craft more targeted therapies in many fields of medicine.

Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Publishing Authors By Initials

For similar cells: blood cells: leukocytes: leukocytes, mononuclear: lymphocytes: lymphocyte subsets: t-lymphocyte subsets research abstracts see: cells: blood cells: leukocytes: leukocytes, mononuclear: lymphocytes: lymphocyte subsets: t-lymphocyte subsets research

PUBMED ID PMID:

MEDLINE DATE:

Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Journal Published:

PUBLICATION TYPE: Review

Journal: Journal of clinical rheumatology : practical repor

VOLUME: 11

Page Numbers: 336-9

Journal Abbreviation: J Clin Rheumatol

ISSN: 1076-1608

DAY: 10

MONTH: Dec

YEAR: 2005

Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Information

Number of References: 11

LANGUAGE: eng

NlmUniqueID: 9518034

Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Keywords Mesh Terms:

KEYWORDS: T-Lymphocyte Subsets

MESH TERMS: immunology

Chemical & Substance for Abstract: Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells. Information

Substance Name: Receptors, Antigen, T-Cell, gamma-delta

Registry Number: 0

Grant and Affiliation Information for Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells.

AFFILIATION: Pharmaceutical Research Institute/Bristol-Myers Squibb, Princeton, NJ 08543, USA. leonard.sigal@bms.com

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Rheumatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Basic science for the clinician 35: CD1, invariant NKT iNKT Cells, and gammadelta T-cells Related Publications

• A pilot trial of external Qigong therapy for arthritis.
• A role for NKG2D in NK cell-mediated resistance to poxvirus disease.
• Basic science for the clinician 27: Toll-like receptors and nucleotide oligomerization domains.
• Basic science for the clinician 30: The immunologic synapse.
• Basic science for the clinician 32: T-cells with regulatory function.
• Basic science for the clinician 35: CD1, invariant NKT (iNKT) Cells, and gammadelta T-cells.
• Basic science for the clinician 36: protecting against autoimmunity: tolerance and aire, the immunologic shadow, and other mechanisms of negative selection in the thymus.
• Basic science for the clinician 37: Protecting against autoimmunity-tolerance: mechanisms of negative selection in the thymus.
• Basic science for the clinician 43: the mitogen-activated protein kinase family in inflammatory signaling.
• Basic science for the clinician 46. Molecular biologic agents in development: possible clinical consequences to rheumatologists.
• Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host.
• Hepatitis B and end-stage liver disease.
• Lateralized neuroleptic-induced side effects are associated with asymmetric visual evoked potentials.
• Letter: Milk of magnesia treatment for acne.
• Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection.
• Molecular biology and immunology for clinicians 15: Antigen presenting cells--class I.
• Molecular biology and immunology for clinicians 16: Dendritic cells and their role in immunology.
• Molecular biology and immunology for clinicians 17: T-cell signal transduction.
• Molecular biology and immunology for clinicians 18: Heat shock proteins/chaperonins.
• Molecular biology and immunology for clinicians 19: Protein purification and synthesis technology.
• Molecular biology and immunology for clinicians 20: Angiogenesis and vascular growth factors and signals.
• Molecular biology and immunology for clinicians 21: The innate immune system: an introduction.
• Molecular biology and immunology for clinicians 22: natural killer cell receptors and activation mechanisms.
• Molecular biology and immunology for clinicians 23: autoimmunity and the superfamilies of tumor necrosis factor and tumor necrosis factor receptor.
• Question about coexisting lyme disease and parvovirus infection.
• RAPID COMMUNICATIONS: Explaining Physical Activity Levels From a Self-Efficacy Perspective: The Physical Activity Counseling Trial.
• Skin conductance responding in schizophrenic patients with abnormal involuntary movements.
• The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination.
• [Phenomenon of the intertransformation of pulse and continuous blood flow in intramural arteries]
• [THE EFFECT OF CHEMOPROPHYLAXIS WITH PHTHIVAZID ON INFECTIVITY AND MORBIDITY OF CHILDREN AND ADOLESCENTS FROM TUBERCULOUS FOCI.]